Vireo Growth (VREOF) Change in Receivables (2020 - 2026)
Vireo Growth (VREOF) reported Change in Receivables of $1.1 million for Q1 2026, up 283.33% on a YoY basis from $286956.5 in Q1 2025, and down 41.22% sequentially from $1.9 million in Q4 2025.
Vireo Growth (VREOF) Change in Receivables (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Change in Receivables data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 283.33% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (up 896.59% YoY), and the FY2025 full-year result was $6.1 million, up 488.6% from the prior year.
- Change in Receivables slipped to $1.1 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.9 million in Q2 2025 to a low of -$2.4 million in Q4 2023.
- A 5-year average of $383347.8 and a median of $221437.0 in 2022 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables surged 3260.33% in 2022 and tumbled 1326.77% in 2024, its largest moves.
- Tracing VREOF's Change in Receivables over 5 years: stood at -$1.6 million in 2022, then tumbled by 43.75% to -$2.4 million in 2023, then soared by 151.16% to $1.2 million in 2024, then soared by 55.53% to $1.9 million in 2025, then plunged by 41.22% to $1.1 million in 2026.
- Business Quant data shows VREOF's Change in Receivables at $1.1 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Sep 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Mar 31, 2025 | -600,000.00 |
| Mar 31, 2025 | -600,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 669,306.00 |
| Sep 30, 2024 | 669,306.00 |
| Jun 30, 2024 | -493,536.00 |
| Jun 30, 2024 | -493,536.00 |
| Mar 31, 2024 | -348,817.00 |
| Mar 31, 2024 | -348,817.00 |
| Dec 31, 2023 | -2.35 Mn |
| Dec 31, 2023 | -2.35 Mn |